Givosiran

(Givlaari®)

Givosiran

Drug updated on 9/4/2024

Dosage FormInjection (subcutaneous; 189 mg/mL)
Drug ClassAminolevulinate synthase 1-directed small interfering RNAs
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adults with acute hepatic porphyria (AHP).

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • Givlaari (givosiran) is indicated for the treatment of adults with acute hepatic porphyria (AHP).
  • This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
  • Reduction in Acute Attack Rates: Givosiran is reported to effectively reduce the rates of acute attacks in patients with Acute Intermittent Porphyria (AIP).
  • Effectiveness in Terminating Recurrent Attacks: Givosiran has demonstrated effectiveness in terminating recurrent attacks of AIP.
  • Non-serious side effects associated with givosiran include fatigue and nausea, with severe side effects like pain also reported.
  • There is limited safety data on the impact of givosiran on renal and liver function, particularly in patients with existing kidney and liver diseases, indicating a need for further research.

Product Monograph / Prescribing Information

Document TitleYearSource
Givlaari (givosiran) Prescribing Information.2023Alnylam Pharmaceuticals, Inc., Cambridge, MA

Systematic Reviews / Meta-Analyses